LRIG1: Leucine-Rich Repeats and Immunoglobulin-Like Domains 1
A negative regulator of receptor tyrosine kinase signaling and tumor suppressor
Gene Information Card
| Symbol | LRIG1 |
|---|---|
| Full Name | Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 |
| Gene Type | Protein coding |
| Chromosomal Location | 3p14.1 |
| NCBI Gene ID | 26018 ncbi.nlm.nih.gov/gene/26018 |
| Ensembl ID | ENSG00000144749 |
| UniProt ID | Q96JA1 |
| OMIM ID | 608868 |
| HGNC ID | 17360 |
| Aliases | LIG1, DKFZp586I1420, MGC117188 |
Description
LRIG1 encodes a transmembrane protein containing leucine-rich repeats and immunoglobulin-like domains. It functions as a negative regulator of receptor tyrosine kinases, including EGFR and MET, by promoting receptor ubiquitination and degradation. LRIG1 is considered a tumor suppressor in various cancers, with loss of expression associated with poor prognosis.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Colorectal cancer | Loss of LRIG1 expression leads to increased EGFR signaling and tumor progression | PMID: 19165229 |
| Breast cancer | Reduced LRIG1 correlates with HER2 overexpression and poor survival | PMID: 20010857 |
| Glioma | LRIG1 downregulation promotes tumor growth via EGFR stabilization | PMID: 16959972 |
| Prostate cancer | LRIG1 loss enhances androgen receptor and RTK signaling | PMID: 21573173 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Skin | 12.5 | Medium |
| Kidney | 8.3 | Medium |
| Lung | 6.1 | Low |
| Brain | 4.7 | Low |
| Liver | 2.1 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK 293 | 15.2 | High expression |
| HeLa | 9.8 | Moderate expression |
| MCF7 | 5.4 | Low expression |
| A549 | 3.1 | Very low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1072C>T (p.Arg358*) | Nonsense | 0.2% in COSMIC | Loss of function |
| c.1546G>A (p.Gly516Arg) | Missense | 0.1% in COSMIC | Unknown significance |
| c.1891_1892insA (p.Thr631Asnfs*12) | Frameshift | 0.05% in COSMIC | Loss of function |
Mutation functional classification
Loss of Function (LOF)
Nonsense and frameshift mutations in LRIG1 result in truncated proteins lacking the transmembrane or cytoplasmic domain, impairing receptor degradation.
Gain of Function (GOF)
No gain-of-function mutations reported in LRIG1.
Dominant Negative (DN)
No dominant-negative mutations reported in LRIG1.
View complete mutation data：
Gene Ontology (GO)
Pathways
• EGFR tyrosine kinase inhibitor resistance (KEGG: hsa01521)
• ErbB signaling pathway (KEGG: hsa04012)
• Proteoglycans in cancer (KEGG: hsa05205)
Protein Summary
LRIG1 is a 1093-amino acid transmembrane protein with 15 leucine-rich repeats and 3 immunoglobulin-like domains in its extracellular region. It interacts with receptor tyrosine kinases such as EGFR and MET, recruiting E3 ubiquitin ligases to promote receptor endocytosis and degradation. LRIG1 acts as a tumor suppressor by attenuating growth factor signaling.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| LRIG1 Knockout HEK293 Cell Line | EDJ-KQ8355 | Human | 26018 | Details Get a Quote |
| LRIG1 Knockout HCT 116 Cell Line | EDJ-KQ33044 | Human | 26018 | Details Get a Quote |
| LRIG1 Knockout A-549 Cell Line | EDJ-KQ34382 | Human | 26018 | Details Get a Quote |
| LRIG1 Knockout HeLa Cell Line | EDJ-KQ34384 | Human | 26018 | Details Get a Quote |
